Incyte | Sustainability Performance
A global biopharmaceutical company focused on oncology and inflammation therapies.
1991
United States
1,001 - 5,000 employees
Pharmaceuticals
$1B - 10B in revenue
$1B - 10B in profitability
Submit or report inaccurate dataDownload Company InsightsⓘBy downloading this report, you'll receive the most insightful and detailed analysis of the company's sustainability performance, compared to its peers. It includes key industry trends, carbon and energy intensity, nature impact, social metrics, and an in-depth look at key risks and controversies.
Sustainability Ranking & Industry Benchmark
#296
Overallⓘ#68
in United Statesⓘ#10
in PharmaceuticalsⓘSustainability Maturity
ⓘSustainability Intent
ⓘOverview
Environmental
Carbon emissionsCarbon certificatesEnergy consumptionWaste ManagementWater ManagementNature and biodiversitySocial
Diversity and InclusionPay GapsHealth and SafetyExternalitiesGovernance
SDG ImpactFinancial Data
Business performanceCapital & innovationAnalyst projections
Leading
Leading
Laggard
Critical
Intensity
Energy consumption (direct) intensity (MWh /$M)
Water consumption intensity (m³ /$M)
Waste generation intensity (tonnes /$M)
Industry Benchmark
10.0
B/M 42.0
26.3
B/M 131.1
0.2
B/M 0.4
Powered by illuminem and GIST Impact
Controversy level
- Incyte Corporation, US oncology biotech (Jakafi/ruxolitinib, Opzelura cream), has faced multiple US class actions over alleged inadequate disclosure of Jakafi patent extension challenges and the contested 2024 sustained share price volatility amid Jakafi generic competition pressure affecting Incyte's US institutional shareholders amid the broader US biotech market normalization.
Sustainability employees
ⓘWe follow the strictest rules to ensure compliance with all the relevant data protection laws, including GDPR. Click here for our Privacy Policy.Total sustainability employees
7-10
ⓘThis value represents the estimated number of employees in a company with sustainability-related roles or job titles, as determined by Illuminem using publicly available data.